JP2022524741A5 - - Google Patents
Info
- Publication number
- JP2022524741A5 JP2022524741A5 JP2021552142A JP2021552142A JP2022524741A5 JP 2022524741 A5 JP2022524741 A5 JP 2022524741A5 JP 2021552142 A JP2021552142 A JP 2021552142A JP 2021552142 A JP2021552142 A JP 2021552142A JP 2022524741 A5 JP2022524741 A5 JP 2022524741A5
- Authority
- JP
- Japan
- Prior art keywords
- selinexol
- succinic acid
- cocrystal
- mixed solution
- morphology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106508A JP2025134935A (ja) | 2019-03-20 | 2025-06-24 | セリネクソールの共結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821203P | 2019-03-20 | 2019-03-20 | |
| US62/821,203 | 2019-03-20 | ||
| PCT/US2020/023530 WO2020191140A1 (en) | 2019-03-20 | 2020-03-19 | Co-crystal forms of selinexor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106508A Division JP2025134935A (ja) | 2019-03-20 | 2025-06-24 | セリネクソールの共結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524741A JP2022524741A (ja) | 2022-05-10 |
| JP2022524741A5 true JP2022524741A5 (cg-RX-API-DMAC7.html) | 2024-11-18 |
Family
ID=70293085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552142A Pending JP2022524741A (ja) | 2019-03-20 | 2020-03-19 | セリネクソールの共結晶形態 |
| JP2025106508A Pending JP2025134935A (ja) | 2019-03-20 | 2025-06-24 | セリネクソールの共結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106508A Pending JP2025134935A (ja) | 2019-03-20 | 2025-06-24 | セリネクソールの共結晶形態 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12559478B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3941588A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022524741A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210141936A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113423468A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016762A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3130107A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020191140A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016762A2 (pt) | 2019-03-20 | 2021-10-19 | Johnson Matthey Public Limited Company | Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883802B2 (en) * | 2009-12-03 | 2014-11-11 | Astrazeneca Ab | Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor |
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| WO2014160686A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
| CA2950485A1 (en) * | 2014-06-30 | 2016-01-07 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
| SG11201700789SA (en) * | 2014-08-15 | 2017-02-27 | Karyopharm Therapeutics Inc | Polymorphs of selinexor |
| US11034675B2 (en) | 2016-01-08 | 2021-06-15 | Dr. Reddy's Laboratories Limited | Solid forms of Selinexor and process for their preparation |
| EP3565813A1 (en) | 2017-01-05 | 2019-11-13 | Watson Laboratories, Inc. | Novel crystalline forms of selinexor and process for their preparation |
| CN107089946B (zh) * | 2017-05-05 | 2020-04-03 | 浙江科技学院 | 一种诺氟沙星与香兰素共晶及其制备方法 |
| BR112021016762A2 (pt) | 2019-03-20 | 2021-10-19 | Johnson Matthey Public Limited Company | Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor |
-
2020
- 2020-03-19 BR BR112021016762-5A patent/BR112021016762A2/pt not_active Application Discontinuation
- 2020-03-19 EP EP20719832.6A patent/EP3941588A1/en not_active Withdrawn
- 2020-03-19 KR KR1020217028384A patent/KR20210141936A/ko not_active Withdrawn
- 2020-03-19 CA CA3130107A patent/CA3130107A1/en active Pending
- 2020-03-19 WO PCT/US2020/023530 patent/WO2020191140A1/en not_active Ceased
- 2020-03-19 CN CN202080013966.2A patent/CN113423468A/zh active Pending
- 2020-03-19 JP JP2021552142A patent/JP2022524741A/ja active Pending
-
2021
- 2021-09-01 US US17/446,664 patent/US12559478B2/en active Active
-
2025
- 2025-06-24 JP JP2025106508A patent/JP2025134935A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7100625B2 (ja) | 置換2-h-ピラゾール誘導体の結晶形、塩型及びその製造方法 | |
| CN115461344B (zh) | 一种glp-1受体激动剂的晶型a及其制备方法 | |
| CN114209699A (zh) | C-met调节剂药物组合物 | |
| TWI675839B (zh) | 一種jak激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
| KR102886764B1 (ko) | Cdk9 억제제의 결정다형 및 이의 제조방법과 용도 | |
| CN108779126A (zh) | 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式 | |
| CN107427503A (zh) | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 | |
| CN101676266B (zh) | 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物 | |
| JP2019504033A (ja) | 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法 | |
| EP3626715A1 (en) | Crystal of benzofuran derivative free base and preparation method | |
| TW201629060A (zh) | 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法 | |
| CN117529313A (zh) | 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 | |
| TW201638090A (zh) | 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法 | |
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| WO2023078451A1 (zh) | 用作cdk7激酶抑制剂的化合物及其应用 | |
| EP3430004A1 (en) | Solid state forms of nilotinib salts | |
| TW201718516A (zh) | 組蛋白去乙醯酶抑制劑之晶形 | |
| JP2024530315A (ja) | Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 | |
| CN108884099B (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
| WO2017041622A1 (zh) | 一种雄性激素受体抑制剂的结晶形式及其制备方法 | |
| JP6761564B2 (ja) | ナトリウム・グルコース共輸送体2阻害薬のl−プロリン化合物、およびl−プロリン化合物の一水和物および結晶 | |
| US12559478B2 (en) | Co-crystal forms of selinexor | |
| HK40072576B (en) | Compound used as kinase inhibitor and use thereof | |
| HK40089264A (en) | Compound used as cdk7 kinase inhibitor and use thereof | |
| WO2022253261A1 (zh) | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |